Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Edgewise Therapeutics sells sevasemten to Servier for up to $2.65 billion
June 1, 2026 8:31 AM EDTEdgewise Therapeutics Inc. (NASDAQ: EWTX) announced it entered into a definitive agreement to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments.
Under the agreement, Servier will acquire all rights to sevasemten, including intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting... More
Servier to acquire Edgewise muscular dystrophy business for $2.65 billion
June 1, 2026 8:30 AM EDTServier announced an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for up to $2.65 billion. The transaction includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments.
The acquisition includes sevasemten, an investigational oral treatment for Becker and... More
